Program overview
Context
Indication: Locally Advanced or Metastatic Breast Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: MediLink Therapeutics (Suzhou) Co., .
Operational Burden Signal
YL202 should be intravenously infused
YL202 should be intravenously infused is flagged as operational burden signal because public records show timeline staleness, operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 1/5
Timeline: 2/5
Recruitment burden: 3/5
Results availability: 0/5
Program risk: 3/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT06439771
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT06439771 | Low Signal (RECRUITING) | stale_update_signal | long_recruitment_duration_signal | Low Signal | few_sites_large_trial_signal | rare_population_signal | strict_eligibility_signal |